# FDA Approves Pfizer IBRANCE (Palbociclib) for HR+/HER2+ Metastatic Breast Cancer

> fda · REPORTED · 2026-07-08

The FDA approved Pfizer's IBRANCE (palbociclib) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for adult patients with HR-positive, HER2-positive locally advanced or metastatic breast cancer, based on the Phase 3 PATINA trial. The approval expands the CDK4/6 inhibitor franchise into the HER2-positive breast cancer setting.

About Pfizer: Pfizer is a global biopharmaceutical company; IBRANCE is its marketed CDK4/6 inhibitor originally approved for HR+/HER2-negative breast cancer, and this new approval targets the HR+/HER2+ metastatic breast cancer population.

- Company: Pfizer
- Sector: oncology
- Primary source: https://www.pfizer.com/news/press-release/press-release-detail/fda-approves-pfizers-ibrance-regimen-hr-her2-metastatic

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.